Filtered By:
Source: CardioBrief
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 307 results found since Jan 2013.
An Expert’s Perspective: Why Salt Is Not Like Tobacco And Why Guidelines Are Tricky
At the center of this week’s renewed debate on salt was Salim Yusuf, the long influential and often controversial cardiology researcher and clinical trialist based at McMaster University in Hamilton, Ontario. I spoke with Yusuf before the publication of the New England Journal of Medicine papers, which include his own two papers from the PURE study. Yusuf was troubled by the tone of the salt debate. He’s no stranger to scientific controversies and intense disagreement, but “scientific criticism is one thing, personal attack is another,” he said. Because he has presented data that suggests that m...
Source: CardioBrief - August 14, 2014 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes american heart association guidelines new england journal of medicine Salim Yusuf salt sodium Source Type: blogs
Study Offers Little Support for an Old Drug
Digoxin is one of the oldest drugs in the cardiovascular arsenal, derived from the foxglove plant and first described in the 18th century by William Withering. It is frequently used in patients with heart failure (HF) and with atrial fibrillation (AF). The few trials supporting its use were performed in HF patients before newer treatments arrived. There have been no good trials in AF. A new observational study published in the Journal of the American College of Cardiology now provides the most detailed perspective on digoxin use in AF. … … Click here to read the full post More…
Source: CardioBrief - August 11, 2014 Category: Cardiology Authors: Larry Husten Tags: Heart Failure Heart Rhythms atrial fibrillation Digitalis Digoxin Source Type: blogs
Principal Investigator Of Suspended Cytori Stem Cell Trials Remains Hopeful
Shares of Cytori Therapeutics took a big bit hit today after the company disclosed in a press release that it had suspended enrollment in its ATHENA and ATHENA II trials. This kind of news is never a good sign, but the principal investigator of the trial tells me that he believes the current problems are surmountable and that the trials are still viable. … Click here to read the full post on Forbes.
Source: CardioBrief - August 6, 2014 Category: Cardiology Authors: Larry Husten Tags: Heart Failure Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Cytori stem cells Timothy Henry Source Type: blogs
Clot Busters For Stroke Gain More Support
Although thrombolysis for ischemic stroke has been widely recognized as beneficial, its use has been limited because of concerns about its effects on patients treated after 3 hours, on older patients, and on patients with mild and with severe strokes. Now a new metaanalysis published in the Lancet offers evidence that the use of thrombolysis should be more aggressively pursued. … Click here to read the full post on Forbes.
Source: CardioBrief - August 6, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery MI/ACS Policy & Ethics alteplase stroke thrombolysis Source Type: blogs
Dutch Investigation Finds Serious Flaws In Influential New England Journal Of Medicine Study
Erasmus Medical Center says it has wrapped up its investigation of Don Poldermans, the disgraced cardiology researcher who was fired for research misconduct. The full extent of the misconduct has never been known, and from an examination of the Erasmus report it appears likely that it never will be known. One major finding– though downplayed in the medical center’s press release– is that the most prestigious and influential publication from the Poldermans’ group, the 1999 publication of the DECREASE 1 study in the New England Journal of Medicine– appears to be riddled with serious problem...
Source: CardioBrief - July 30, 2014 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics guidelines Poldermans scientific misconduct Source Type: blogs
Death By Running: It’s The Heat And Not The Heart
The growing popularity of marathons and other extreme sports has sparked worries about the potential dangers of these activities. The popular press and medical research have both focused on the risk of cardiac arrest and other heart rhythm problems. But that concern may be misdirected. A new study from Israel published in the Journal of the American College of Cardiology finds that a much more serious danger may be heat stroke, which is defined as a core body temperature above 104 or 105 degrees associated with multiorgan dysfunction. … Click here to read the full post on Forbes.
Source: CardioBrief - July 28, 2014 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms Policy & Ethics Prevention, Epidemiology & Outcomes endurance exercise heat stroke marathons running Source Type: blogs
Running: Any Amount Is Good And More May Not Be Better
Although there is broad agreement that exercise is beneficial there has been substantial uncertainty about how much exercise is good for you. Recently some studies have suggested that too much exercise may actually reduce the benefits of exercise. Now a new study published in the Journal of the American College of Cardiology finds that even a small amount of exercise, even running for as little as 5 minutes a day, may be just as healthful as more exercise. … Click here to read the full post on Forbes.
Source: CardioBrief - July 28, 2014 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes exercise marathons running Source Type: blogs
Study Finds Flaws in New Treatment For Blood Clots
In recent years, catheter-directed thrombolysis (CDT) has been added to the current standard of anticoagulation therapy in some patients with deep vein thrombosis (DVT). The hope was that CDT would help reduce the high rate of post-thrombotic syndrome (PTS), but now an observational study finds no benefits and some important disadvantages associated with CDT. In a report published in JAMA Internal Medicine, Riyaz Bashir and colleagues analyzed data from more than 90,000 patients hospitalized for DVT, 3649 of whom received CDT plus anticoagulation. … Click here to read the full post on Forbes.
Source: CardioBrief - July 22, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery anticoagulation blood clots thrombolysis Source Type: blogs
FDA Places Clinical Hold On Phase 3 Trial Of Novel Anticoagulant
A highly promising novel anticoagulant system now appears to be in serious difficulty. Regado Biosciences announced today that the FDA had placed a “clinical hold” on patient enrollment and dosing in the REGULATE-PCI trial, which is testing the Revolixys anticoagulation system. Revolixys consists of the Factor IX inhibitor pegnivacogin and an agent, anivamersen, which reverses its anticoagulant effect. REGULATE-PCI is a phase 3 trial comparing Revolixys to bivalirudin (Angiomax, The Medicines Company) in 13,000 patients undergoing PCI. … Click here to read the full post on Forbes.
Source: CardioBrief - July 10, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics anticoagulants FDA Regado Biosciences The Medicines Company Source Type: blogs
Study Explores Expanded Use For Edwards’ And Medtronic’s New Heart Valves
In the last few years transcatheter aortic valve replacements from Edwards Lifesciences and Medtronic have entered the marketplace and now offer an alternative to surgery for some patients. Now these valves are being considered for use in patients who have already undergone surgery but whose bioprosthetic valves have failed. Although surgeons and patients increasingly prefer bioprosthetic valves to mechanical valves, the chief drawback to the bioprosthetic valves is that they may eventually deteriorate, which means that more and more physicians and patients will inevitably be faced with the dilemma of how best to treat degenerated More…
Source: CardioBrief - July 9, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery aortic valve replacement TAVI TAVR Source Type: blogs
ESC Hot Lines: First Real Data On Promising Novartis Heart Failure Drug
The first real details about the much-anticipated novel new heart failure drug from Novartis will kick off this year’s Hot Line sessions at the annual meeting of the European Society of Cardiology in Barcelona, Spain. The meeting runs from August 30 until September 3. As I have previously reported, the PARADIGM-HF trial was stopped because of a highly statistically significant reduction in cardiovascular mortality in patients taking LCZ696 (a novel, first-in-class Angiotensin Receptor Neprilysin Inhibitor) instead of the current gold standard of treatment, an ACE inhibitor…. … Here is the complete l...
Source: CardioBrief - July 1, 2014 Category: Cardiology Authors: Larry Husten Tags: Heart Failure Heart Rhythms Interventional Cardiology & Surgery MI/ACS People, Places & Events ESC Hot Lines Source Type: blogs
Study Offers Reassurance About Newer Drug-Eluting Stents
Drug-eluting stents (DES) have been viewed as a great advance over earlier stents and balloon angioplasty because they result in many fewer cases of restenosis. But enthusiasm for the first generation of DES was somewhat curbed due to reports of late stent thrombosis (ST), a rare but very dangerous complication. Now findings from a large ongoing registry study provide some reassurance about the long-term safety of the new generation of drug-eluting stents in patients with heart attacks (STEMI). The results are published in the Journal of the American College of Cardiology. SCAAR (Swedish Coronary Angiography and Angio...
Source: CardioBrief - July 1, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery MI/ACS drug-eluting stents heart attacks STEMI stent thrombosis Source Type: blogs
Mobile Cardiovascular Screening Programs Come Under Fire
It seems like a no brainer. Cardiovascular screening is the #1 killer in the world so broad screening of the general population must be a good idea, right? Wrong, says the consumer group Public Citizen, at least when such screening is performed indiscriminately. Somewhat surprisingly, Public Citizen, which is often held at arm’s length by mainstream medicine, gained some support for its position from a major cardiology organization. In its statement Public Citizen urged 20 hospitals to sever their involvement in a mobile cardiovascular screening program. The HealthFair Cardiovascular Screening Packages are unet...
Source: CardioBrief - June 23, 2014 Category: Cardiology Authors: Larry Husten Tags: Uncategorized Source Type: blogs
Yet Another Delay For Boston Scientific’s Watchman Device
Boston Scientific hopes the third time will be the charm. The company disclosed on Tuesday yet another obstacle in the path to approval for its novel Watchman left atrial appendage closure device for the prevention of stroke in patients with atrial fibrillation. Although it has already been before two FDA advisory panels, the company said that it had been informed by the FDA that it will need to undergo yet another advisory panel before gaining approval. … Click here to read the full post on Forbes.
Source: CardioBrief - June 18, 2014 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms Interventional Cardiology & Surgery People, Places & Events atrial fibrillation Boston Scientific FDA stroke prevention Watchman Source Type: blogs
FDA Approves Second Generation Heart Valve From Edwards Lifesciences
The next phase of the burgeoning and rapidly maturing transcatheter aortic valve replacement (TAVR) market has begun. Edwards Lifesciences announced on Monday afternoon that the FDA had approved its second generation Sapien XT TAVR device for the treatment of high-risk and inoperable patients suffering from severe symptomatic aortic stenosis (AS). … Click here to read the full post on Forbes.
Source: CardioBrief - June 16, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics CoreValve Edwards Medtronic Sapien TAVR Source Type: blogs
